Clinical Approach to Mast Cell Activation Syndrome: A Practical Overview
No Thumbnail Available
Identifiers
Date
2021-01-01
Authors
Matito, A.
Escribese, M. M.
Longo, N.
Mayorga, C.
Luengo-Sanchez, O.
Perez-Gordo, M.
Matheu, V
Labrador-Horrillo, M.
Pascal, M.
Seoane-Reula, M. E.
Advisors
Journal Title
Journal ISSN
Volume Title
Publisher
Esmon publicidad s a, dept allergy & clin immunol, clin univ navarra
Abstract
The diagnosis of mast cell activation syndrome (MCAS) is defined by 3 criteria: (1) typical clinical signs and symptoms of acute, recurrent (episodic), and systemic mast cell activation (MCA); (2) increase in tryptase level to >20% + 2 ng/mL within 1-4 hours after onset of the acute crisis; and (3) response of MCA symptoms to antimediator therapy. Classification of MCAS requires highly sensitive and specific methodological approaches for the assessment of clonal bone marrow mast cells at low frequencies. The Spanish Network on Mastocytosis score has been used successfully as a predictive model for selecting MCAS candidates for bone marrow studies based on a high probability of an underlying clonal mast cell disorder. In this article, we propose a diagnostic algorithm and focus on the practical evaluation and management of patients with suspected MCAS.
Description
MeSH Terms
DeCS Terms
CIE Terms
Keywords
Anaphylaxis,  , Antimediator therapy,  , Mast cell activation syndrome,  , Mast cell mediator release-related symptoms,  , Tryptase, Indolent systemic mastocytosis, European competence network, Serum tryptase, Peripheral-blood, Venom immunotherapy, Bone-marrow, Human skin, Kit d816v, Anaphylaxis, Disorders